Top Stock Reports for JPMorgan Chase, Salesforce & Vertex Pharmaceuticals
https://www.zacks.com/commentary/2231762/top-stock-reports-for-jpmorgan-chase-salesforce-vertex-pharmaceuticals?cid=CS-ZC-FT-research_daily-2231762
Feb 26, 2024 - Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Vertex Pharmaceuticals Incorporated (VRTX).
0
GSK vs. VRTX: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2236145/gsk-vs-vrtx-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2236145
Mar 05, 2024 - GSK vs. VRTX: Which Stock Is the Better Value Option?
0
2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
https://www.fool.com/investing/2024/03/17/2-no-brainer-healthcare-stocks-to-buy-with-1000/?source=iedfolrf0000001
Mar 17, 2024 - It's always a good time to buy great stocks with excellent prospects.
0
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2245680/vertex-pharmaceuticals-vrtx-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2245680
Mar 25, 2024 - In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
0
Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul
https://www.fool.com/investing/2024/04/05/got-1000-2-bulletproof-stocks-to-buy-in-2024-and/?source=iedfolrf0000001
Apr 05, 2024 - These businesses are booming.
0
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
https://www.fool.com/investing/2024/04/15/heres-at-least-1-new-reason-to-buy-vertex-pharma/?source=iedfolrf0000001
Apr 15, 2024 - Vertex just laid claim to an asset that might be very valuable.
0
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
https://www.zacks.com/stock/news/2256355/bluebird-blue-underperforms-industry-ytd-amid-challenges?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2256355
Apr 16, 2024 - bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
0
2 Top Growth Stocks to Buy Right Now and Hold Forever
https://www.fool.com/investing/2024/04/28/2-top-growth-stocks-to-buy-now-and-hold-forever/?source=iedfolrf0000001
Apr 28, 2024 - These healthcare stocks can provide enviable long-term portfolio growth.
0
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
https://www.zacks.com/stock/news/2267448/vertex-pharmaceuticals-vrtx-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2267448
May 02, 2024 - The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $400.16, representing a -0.49% change from its previous close.
0
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
https://www.zacks.com/stock/news/2272460/bluebird-blue-tops-on-q1-sales-zynteglo-progresses-well?cid=CS-ZC-FT-analyst_blog|earnings_article-2272460
May 10, 2024 - bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
0
Pages: 12
Page 1